Mapi Pharma Presents Glatiramer Acetate Depot (GA Depot) Results at the 8th Joint ACTRIMS-ECTRIMS Meeting MSVirtual2020
September 10, 2020 08:00 ET
|
Mapi Pharma Ltd.
90% of relapsing remitting multiple sclerosis (RRMS) patients on GA Depot demonstrated no evidence of disease activity (NEDA) at four years Data suggest that GA Depot may also have potential as a...
Mapi Pharma and Mylan Strengthen Partnership to Develop and Commercialize Once-Monthly Glatiramer Acetate Depot for Relapsing-Remitting Forms of Multiple Sclerosis
June 15, 2020 07:00 ET
|
Mapi Pharma Ltd.
NESS ZIONA, Israel, June 15, 2020 (GLOBE NEWSWIRE) -- Mapi Pharma Ltd., a privately held, fully integrated, late clinical stage biopharmaceutical company today announced an additional $20 million...
Mapi Announces First Patient Enrolled in the Phase III Clinical Trial of GA Depot for Relapsing Multiple Sclerosis (RMS)
October 28, 2019 08:00 ET
|
Mapi Pharma Ltd.
NESS ZIONA, Israel, Oct. 28, 2019 (GLOBE NEWSWIRE) -- Mapi Pharma Ltd. announced today that the first patient has been enrolled in its Phase III study with GA Depot for relapsing forms of multiple...
Mapi Pharma to Present Series of Recent Advancements for Treating Multiple Sclerosis (MS) at ECTRIMS 2019
September 04, 2019 07:00 ET
|
Mapi Pharma Ltd.
Results for Glatiramer Acetate (GA) Depot 3 year analysis in RRMS, GA Depot safety results in RRMS and PPMS, and novel anti-BMP for remyelination will be presented ECTRIMS 2019 to be held in...
Mapi Pharma to Build a New Sterile Injectable Production Plant for GA Depot in Jerusalem
July 15, 2019 07:30 ET
|
Mapi Pharma Ltd.
NESS ZIONA, Israel, July 15, 2019 (GLOBE NEWSWIRE) -- Mapi Pharma Ltd., a fully integrated, late-stage clinical development biopharmaceutical company announced today that is has signed a long term...
Mapi Pharma to Present Phase II Extension Results of Glatiramer Acetate Depot (GA Depot) at the 2019 AAN Annual Meeting in Philadelphia on May 7 2019
April 30, 2019 09:39 ET
|
Mapi Pharma Ltd.
NESS ZIONA, Israel, April 30, 2019 (GLOBE NEWSWIRE) -- Mapi Pharma Ltd., a fully integrated, late-stage clinical development biopharmaceutical company will present two year clinical data from its...
Mapi Pharma Receives Government of Israel Funding for the Establishment of a Finished Dosage Form Facility for the Manufacturing of GA Depot Pharmaceuticals
March 18, 2019 08:00 ET
|
Mapi Pharma Ltd.
NESS ZIONA, Israel, March 18, 2019 (GLOBE NEWSWIRE) -- Mapi Pharma Ltd., a fully integrated, clinical, late stage biopharmaceutical company, announced today that it has received complementary...
Mapi Pharma to Host Key Opinion Leader Meeting on Long Acting Glatiramer Acetate (GA Depot) for Primary Progressive Multiple Sclerosis and New Treatments for MS
February 21, 2019 10:30 ET
|
Mapi Pharma Ltd.
NESS ZIONA, Israel, Feb. 21, 2019 (GLOBE NEWSWIRE) -- Mapi Pharma Ltd., a fully integrated, clinical late stage biopharmaceutical company, announced today that it will host a Key Opinion Leader...
Mapi Pharma Ltd. Announces Closing of $10 Million Investment by Zhejiang Jingxin Pharmaceutical Co.
November 05, 2018 09:00 ET
|
Mapi Pharma Ltd.
NESS ZIONA, Israel, Nov. 05, 2018 (GLOBE NEWSWIRE) -- Mapi Pharma Ltd., a privately held, fully integrated, clinical stage biopharmaceutical company has completed an equity investment of $10 million...
Mapi Pharma Presents Phase II Extension Results of Glatiramer Acetate Depot (GA Depot) at ECTRIMS 2018 in Berlin
October 09, 2018 08:00 ET
|
Mapi Pharma Ltd.
81.8% Patients on GA Depot Demonstrated No Evidence of Disease Activity (NEDA) at 2 years GA Depot Has Potential to Address Multiple Sclerosis Treatment Burden and Improve Patient Compliance ...